市場調查報告書
商品編碼
1268661
2023-2030美國致幻蘑菇市場規模,份額和趨勢分析報告,各產品(淋巴球菌屬,Chathumnus 屬,石松屬),形式(乾燥,加工),應用(脫癮,休閒),細分市場預測U.S. Psychedelic Mushroom Market Size, Share & Trends Analysis Report By Product (Psilocybe, Gymnopilus, Panaeolus), By Form (Dried, Processed), By Application (De-addiction, Recreational), And Segment Forecasts, 2023 - 2030 |
根據 Grand View Research, Inc. 的最新報告,美國致幻蘑菇市場規模到 2030 年將達到 43.21 億美元,2023 年至 2030 年的複合年增長率為 11.3%,預計還會增長。
在美國,致幻蘑菇和其他植物致幻劑的使用正在獲得認可,並且越來越多的運動將其使用合法化。 一些城市和州已經將這些物質合法化或合法化,導致興趣和需求激增。
這些產品在治療各種精神疾病(例如抑鬱症,焦慮症,創傷後應激障礙和成癮症)方面顯示出可喜的效果。 未來,如果對其治療效果的研究進一步推進,預計需求將進一步增加。
主要用途是治療抑鬱症和焦慮症。 這種蘑菇中的活性成分 psilocybin 已被證明可以緩解抑鬱和焦慮的症狀,並誘導人格和行為的長期積極變化。 因此,裸蓋菇素有望用於治療其他精神疾病,如 PTSD,成癮和晚期醫學焦慮症。
在美國,人們對心理健康和幸福感的認識不斷提高,這是推動致幻蘑菇需求的一個主要因素。 抑鬱症和焦慮症等精神疾病的傳統療法並不適用於所有人,導致許多人尋求幻覺療法等替代療法。
此外,隨著人們對合成藥物的潛在風險和副作用的認識不斷提高,人們對天然療法和植物療法的興趣也越來越大。 裸蓋菇素是一種在致幻蘑菇中發現的天然精神活性化合物,幾個世紀以來,土著文化一直將其用於精神病學和治療目的。 隨著人們對自然療法和替代療法的興趣增加,對致幻蘑菇的需求預計將繼續增長。
致幻蘑菇也有望用於治療叢集性頭痛,叢集性頭痛很嚴重且通常對常規治療有抵抗力。 裸蓋菇素已被證明可以降低一些患者叢集性頭痛的頻率和嚴重程度,為患有這種衰弱性疾病的患者帶來新的希望。
The U.S. psychedelic mushroom market size is expected to reach USD 4,321.0 million by 2030, grow at a CAGR of 11.3% from 2023 to 2030 according to a new report by Grand View Research, Inc. The use of psychedelic mushrooms and other plant-based entheogens is gaining acceptance in the U.S., with a growing movement to decriminalize their use. Several cities and states have taken steps to legalize or decriminalize these substances, leading to a surge in interest and demand.
These products have shown promising results in treating various mental health conditions such as depression, anxiety, PTSD, and addiction. As further research is conducted on their therapeutic potential, demand for these substances is likely to increase.
The primary application of these products offer treatment of depression and anxiety disorders. Psilocybin, the active ingredient in these mushrooms, has been found to alleviate symptoms of depression and anxiety and even induce long-term positive changes in personality and behavior. This has sparked growing interest in the use of psilocybin as a potential treatment for other mental health conditions such as PTSD, addiction, and end-of-life anxiety in patients with terminal illnesses.
The growing awareness for mental health and well-being in the U.S. is a major factor driving the demand for psychedelic mushrooms. Traditional treatments for depression, anxiety, and other mental health conditions may not work for everyone, prompting many individuals to seek out alternative therapies, such as psychedelic therapy.
Moreover, there is an increasing interest in natural and plant-based remedies, as people become more aware of the potential risks and side effects of synthetic drugs. Psilocybin, the natural psychoactive compound found in psychedelic mushrooms, has been used for centuries by indigenous cultures for spiritual and therapeutic purposes. As the interest in natural and alternative therapies grows, the demand for psychedelic mushrooms is expected to continue increasing.
Psychedelic mushrooms also offer a potential treatment for cluster headaches, which are severe and often resistant to traditional treatments. Psilocybin has demonstrated effectiveness in reducing the frequency and severity of cluster headaches in some patients, offering new hope for individuals who suffer from this debilitating condition.